Five developments in oncology targets
Drug Target Review explores some of the newest oncologic drug targets, including those for glioblastoma, lung cancer and breast cancer.
List view / Grid view
Articles
A circuit involved in itching: from skin to sensory neurons
Dr Santosh Mishra and Srisruti Bontala explain how they discovered a new cutaneous-nerve pathway for allergic itch in atopic dermatitis.
Five of the most recent microscopy developments
Drug Target Review highlights five of the latest imaging advancements in the field of microscopy.
Revealing the genetic signature of neurodegenerative disease
Which immune cells contribute towards immune-induced neurodegeneration and how could this knowledge enable conditions such Alzheimer’s and multiple sclerosis to be treated?
Drug side effects: an open source tool to predict adverse reactions
Researchers who developed a machine learning algorithm to predict the adverse effects of new drug compounds have released it as an open source tool.
Prophylactics for COVID-19 – known and unknown
This article outlines the ideal scientific research that should be conducted to design a prophylactic to combat COVID-19.
The hope of rejuvenation: using plasma to reverse ageing in mice
Researchers have found that a plasma exchange process can act as a molecular reset button for old blood, improving the health of ageing mice.
From inception to conclusion: how digitalisation is impacting drug development
Phoebe Chubb explores how digitalisation is shaking up the world of drug discovery and development by increasing productivity and reducing human error.
The coronavirus: seasonality and host-specific action of a “sexy” killer
Dr Ulrich Kutschera outlines why more studies are necessary before the spread and deadliness of the novel coronavirus is fully understood.
Unlocking the power of machine learning for small molecule drug discovery
Rick Wagner of ZebiAI and Patrick Riley of Google Accelerated Science (GAS) discuss the development and benefits of a new machine learning drug discovery platform.
Targeting SARM1 to protect vision across retinal degenerative diseases
Dr Sarah Doyle and Dr Ema Ozaki outline their research into SARM1 and why it presents an attractive target for treating retinal degeneration.
3D bioprinting COVID-19 lung models for drug development
Keith Murphy, CEO of Viscient Biosciences, discusses the process of developing a 3D bioprinted tissue model and their potential in developing therapeutics for COVID-19 and other diseases.
Why are women underrepresented in COVID-19 research authorship?
An analysis of papers relating to COVID-19 has found that female researchers make up a third of authors. Here, the potential reasons behind this figure are explored and a possible solution to encourage equality.
What immuno-oncology research can tell us about COVID-19
Dr Jing Watnick discusses how lessons learnt from cancer immunotherapy treatments could be applied to the development of COVID-19 therapies.
Antibody library screening: high throughput strategies
As the number of antibody discovery platforms and formats expands, various characteristics must be rigorously screened for and taken into consideration when deciding which hits to progress to successful development. The earlier in the antibody discovery pathway the assessment is carried out, the greater the hit enrichment and selection will…